Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (May 2015)
23 slides from Can-fite Biopharma's investor presentation, May 29, 2015
Slide 1: Can-Fite Presentation — May 2015
‘ CANFITE BioPharma Ltd. Can-Fite Presentation — May 2015 ‘Small Molecules For Big Clinical Needs™ (NYSE MKT:CANF) (TASE:CFBI)
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time
Slide 3: Advanced clinical stage drug development company
| Advanced clinical stage drug development company * Phase Il and Phase Ii/iII clinical studies Small molecule drugs * Autoimmune Inflammatory diseases * Cancer * Sexual Dysfunction Company Operations * Headquarters and Discovery Labs ~ Petach-Tikva, Israel * Drug Development & Clinical Operations —
Slide 4: Concept to Technology: Why Cancer Does Not Metastasize to Muscle
; F Concept to Technolog Why Cancer Does Not Metastasize to Muscle? 2 <S ———— ss Ss exc pee Apoptosis ecient) “aM A, Adenosine Receptor (AAR) (NYSE MKT:CANF) (TASE:CFBI) CANFITE a BioPharma Ud.
Slide 5: Platform Technology
Platform Technolo * Therapeutic Target * Az adenosine receptor (A3AR) * Highly expressed in inflammatory and cancer cells * Drug product * Small molecules * Orally bioavailable drugs * Therapeutic Effect * Anti-inflammatory and anti-cancer effects in Phase II studies; Excellent safety profile * ABAR
Slide 6: Drug Development Pipeline
Drug Development Pipeline Indication/Drug Pre-clinical Phase! Phasell Phase Ill Inflammation Psoriasis - CF101 Rheumatoid Arthritis - CF101 Oncology Liver Cancer - CF102 Sexual Dysfunction CF602 (NYSE MKT:CANF) (TASE:CFBI) CANFITE 6 BioPharma Eta.
Slide 7: Regional out-licensing deals
e Pa Corpo ership Regional out-licensing deals o SEIKAGAKU CORPORATION [Traded on the Tokyo Stock Exchange (Ticker:4548)) © Exclusive license to develop and commercialize CF101 in Japan * Up to $20 M in upfront, milestone and annual payments ($7.5M received to date) * Up to 12% royalties KANG DONG r
Slide 8: CF101 — Anti-Inflammatory Effect
CF101 — Anti-Inflammatory Effect Properties Anti-Inflammatory Effect . © Highly Selective AsAR Agonist Proof of concept in pre-clinical * Nucleoside derivative pharmacology studies: Rheumatoid Arthritis Osteoarthritis Inflammatory Bowel Disease Uveitis © Molecular weight - 510.29 © Water insoluble *
Slide 9: Rheumatoid Arthritis - Positive Data from Phase II Study
ritis - Positive Data from Phase II S Rheumatoid A ly Phase Ilb study, Placebo controlled, 79 patients, enrolled based on the biomarker : All Patients Patients with No Prior Systemic Therapy 80% 80% @ CF101 (n=8) 1B Placebo (n=8) g 3 & 60% o 4 8 @ 2 60% 2 p=0.035 ‘Treatment week ra 2 8 @Wcrio1 |B Pl
Slide 10: CF101 - Psoriasis Phase II/III Study Protocol
CF101 - Psoriasis Phase ll/Ill - Study Protocol * Double-blind, placebo-controlled study to test efficacy of CF101 in 300 patients with moderate-to-severe plaque psoriasis © 3.arms: 1 mg, 2 mg and of CF101. and placebo * allpatients receiving placebo were switched to either 1. mg or 2 mg CF101 after
Slide 11: Psoriasis - Interim Data
Psoriasis - Interim Data PGA PASI 75 60) —e cFIO11mg 2mgvs1mg 60) cFIO11 mg e CFiO1 2mg P0.0153, oe CFIO2mg 50] -O- Plecebo 50] Oe Placebo ° =O Placebo/t mg == Placebo!t mg Placebo/2 mg sO» Placebo/2 mg Percent of PGA Response Percent of PGA Response 8 2 20 10 10 0 0 o 4 8 2 6 m0 2m o 4 8 2 6 20 2%
Slide 12: Psoriasis Phase II/III - Segment
Psoriasis Phase II/IIl - Segment 2 ® Based on the interim analysis data patients were randomized into the 2 mg and the placebo groups © The study period has been extended to 32 weeks ® >200 patients have been enrolled and data released (NYSE MKT:CANF) (TASE:CFBI) CANFITE BioPharma Ltd.
Slide 13: Psoriasis — Data from Phase II/III Study
Psoriasis — Data from Phase II/IIl Study * The study did not achieve the primary endpoint of significant improvement in PASI 75 at 12 weeks. * Excellent safety profile in all tested dosages * Weeks 12 to 32 Positive Data Findings: > PASI 75 - 35.3% by 32 weeks of treatment; linear response > PASI me
Slide 14: PASI Scores — Linear Improvement Over Weeks
PASI Scores — Linear Improvement Over 32 Week PASI Scores through 32 Weeks of CF101 Treatment PASI 50 60% | —e=PASI75 —B-PASI90 gy 5% —te-Past 100 5 B 40% 3 5 30% g = EI a 2 635 16 20 24 28 32 Treatment Week (NYSE MKT:CANF) (TASE:CFBI) CANFITE BioPharmaltxd.
Slide 15: PASI Response in Treatment-Naive Patients
F PASI 90 Response in Treatment-Naive Patients Statistically Significant PASI 90 Response 30% a , -HENo prior systemic therapy 26.9% -®-Prior systemic therapy 25% g PASI 90 (% of patients) g § g g g 20 24 28 32 Treatment Week (Open Label Period) & (NYSE MKT:CANF) (TASE:CFBI) CANFITE BioPharmalktd.
Slide 16: CF101 compared with Otezla and placebo
57.1% 24.7% 10.6% CF101, Can-Fite at week 32 at week 32 at week 32 no plateau at week 32. no plateau at week _—no plateau at week 32 32 “571% 11.4% Not analyzed at week 16 Otezla*, Celgene at week 24 as there were too start to plateau at week 16.7% few participants ae at week 24 at week 16 Placebo F
Slide 17: CF101 Safety Data - Comparable to Placebo
CF101 Safety Data - Comparable to Placebo CT Vital Signs No significant change No significant change ECG No significant change No significant change Clinical Laboratory No significant change No significant change Any Adverse Event (AE) 25.5% 19.6% Infection AE 6.9% 8.8% “Related” AE 6.9% 4.1% Modera
Slide 18: CF102 — Anti-Cancer Effect
CF102—-A\ Properties Anti-Cancer Effect * Highly Selective A3AR Agonist Proof of concept in pre-clinical pharmacology studies: © Hepatocellular Carcinoma * Colon Carcinoma * Prostate Cancer * Orally bioavailable * Melanoma * Half life time in blood — 12 hours * Nucleoside derivative © Molecular weig
Slide 19: Liver Cancer — Phase II Global Study Ongoing
Liver Cancer — Phase II Global S ly Ongoin, Phase Il - Ongoing Patient enrolment for a global Phase II study has been initiated and designed as follows: * Second-Line Treatment (7 * Advanced Hepatocellular Carcinomiay Child:Pugh B ZEN vera + 78 patients; DER ss + US, Europe and Israel LD Phase I/II
Slide 20: Sexual Dysfunction
Sexual Dysfuncti Chemical Structure Properties ¢ A3AR allosteric modulator seq © Molecular weight — 411.34 cy 7 ° Water insoluble a SC) © Orally bioavailable © Belong to the family of imidazoquinoline derivatives 1H-Imidazo[4,5-c]quinolin-4-amine Derivatives Current status * Manufacturing of CF602 t
Slide 21: CF602 Improvement of Erectile Dysfunction
ement of Erectile Dysfuncti —Impr Diabetic Rat Model Intra-cavernous pressure (ICP)/mean arterial pressure (MAP) ratios MI Control 24h WCF 602 24h HE Control 5d @mMCF 602 5d 03. “ Soe : go a < 2 © 04 2 0.0. (NYSE MKT:CANF) (TASE:CFBI) CANFITE a BioPharma Ltd.
Slide 22: Mechanism of Action
Mechan of Action CF602 acts as a vaso-relaxant to promote smooth muscle relaxation and penile erection CF602 Histological evaluation using a Masson Trichrome stain for smooth muscle detection in Corpus Cavernous blood vessels in an erectile dysfunction model in diabetic rats (NYSE MKT:CANF) (TASE:CF
Slide 23: Spotlight Milestones
Spotlig! Milestones Milestone Estimated Market Size* Entry into an Acquisition Agreement with a Medical Device Company by Can-Fite Subsidiary Q2/2015 N/A Ophthalix Submission of Phase III Rheumatoid Arthritis Clinical Study Protocol to IRB (SERS | SEED TOI Completion of Psoriasis Clinical Study Prot
Can-Fite BioPharma — Investor Presentation (May 2015) on 6ix